Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen    BIIB

BIOGEN (BIIB)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/13/2018 02/14/2018 02/15/2018 02/16/2018 02/20/2018 Date
316.99(c) 296.08(c) 299.38(c) 291.87(c) 287.45(c) Last
732 923 5 426 402 3 040 883 2 943 057 2 004 460 Volume
+0.11% -6.60% +1.11% -2.51% -1.51% Change
More quotes
Financials ($)
Sales 2018 13 009 M
EBIT 2018 6 975 M
Net income 2018 4 607 M
Debt 2018 436 M
Yield 2018 -
Sales 2019 13 431 M
EBIT 2019 7 281 M
Net income 2019 4 821 M
Finance 2019 5 132 M
Yield 2019 -
P/E ratio 2018 13,10
P/E ratio 2019 12,43
EV / Sales2018 4,78x
EV / Sales2019 4,22x
Capitalization 61 749 M
More Financials
Company
Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders.Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for... 
Sector
Pharmaceuticals
Calendar
04/26Earnings Release
More about the company
Surperformance© ratings of Biogen
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOGEN
02/19Rare Haematology Market Trend to 2025 Profiling PRA Health Sciences, Bayer He..
AQ
02/16BIOGEN : and Ionis Pharmaceuticals, Inc. - The New England Journal of Medicine P..
AQ
02/16BIOGEN : and Ionis Pharmaceuticals, Inc. - The New England Journal of Medicine P..
AQ
02/15BIOGEN : Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Is..
AQ
02/15BIOGEN : slips on Phase III AD studies
AQ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
02/12BIOGEN : Norway to buy Biogen's Spinraza medicine - broadcaster NRK
RE
02/12American College of Rheumatology recommends biosimilars for rheumatic disease
AQ
02/09BIOGEN : Stake Increased by Factory Mutual Insurance Co.
AQ
02/07BIOGEN : to Present at the Leerink Partners 7th Annual Global Healthcare Confere..
AQ
More news
Sector news : Biopharmaceuticals
08:48aNOVARTIS : Builds Up R&D -- WSJ
DJ
08:48aABBVIE : FTC Clout Tested in Suit Versus Drugmaker -- WSJ
DJ
02/20MERCK : and Partners Start EUR20 Million Israel Biotech Fund
DJ
02/19BASF to face millions in extra costs in UK each year from Brexit - Handelsbla..
RE
02/19UK shares retreat as Reckitt disappoint
RE
More sector news : Biopharmaceuticals
4-Traders Strategies on BIOGEN 
BIOGEN IDEC  - 2014
Back on a stimulating support
BUY
BIOGEN IDEC - 2013
The bullish trend is not over
BUY
More Strategies
Latest Tweets
02/20Pharmalot.. Pharmalittle.. Good Morning... headlines & coffee are served... 
02/20Optic Neuritis - Pipeline Insight, 2018 Featuring 2-BBB Medicines, Biogen, Bi.. 
02/20Optic Neuritis - Pipeline Insight, 2018 Featuring 2-BBB Medicines, Biogen, Bi.. 
02/20Biogen CEO calls share slump an overreaction to Alzheimer’s trial
6
02/20Biogen chief says market overreacted to increased enrollment in aducanumab st.. 
More tweets
Qtime:129
News from SeekingAlpha
02/20BIOTECHS : Still Well Placed For More Gains 
02/20Biogen chief says market overreacted to increased enrollment in aducanumab st.. 
02/19VALUATION DASHBOARD : Healthcare - Update 
02/15FDA issues draft industry guidance for early-stage Alzheimer's disease 
02/15Selling Into A Void - Athersys Moves In Ignorance 
Chart BIOGEN
Duration : Period :
Biogen Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Technical analysis trends BIOGEN
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 381 $
Spread / Average Target 31%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Alisha A. Alaimo Senior Vice President-US Therapeutic Operations
Jeffrey D. Capello Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN-7.06%61 749
CSL LIMITED7.22%55 816
ALEXION PHARMACEUTICALS3.02%26 706
GRIFOLS SA-4.40%18 275
BIOMARIN PHARMACEUTICAL-5.19%14 924
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%6 688